About
Basic Data Updated:
24 days agoBiocon Limited, a biopharma company, is known for its production of generic APIs (Active Pharmaceutical Ingredients) that are distributed in the markets of the United States and Europe. In addition, it is also responsible for the manufacturing of bio-similar insulins, which are available in India as branded formulations and in both bulk and formulation forms. From discovery to development and commercialization, Biocon Limited offers a wide range of bio-pharmaceutical solutions. Its revenue streams are diverse, including small molecule APIs and formulations, biologics, and branded formulations, with a strong presence in both domestic and global markets. The company has collaborated with Mylan for the development and commercialization of bio-similar insulin analogues, and has previously partnered with Mylan for the development and commercialization of monoclonal antibodies and recombinant proteins.
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Website12224421
- Telephone12224421
- Email Address12224421
- Social Media12224421
Financials of Biocon Limited
Biocon Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 17.6% increase. The company also saw a substantial improvement in profitability, with a 3208.25% increase in profit. The company's net worth Soared by an impressive increase of 34.88%.
Corporate Structure
Unlock access to Biocon's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
People in Biocon Limited
Unlock and access historical data on people associated with Biocon, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Executive Team (2)
SM
Siddharth Mittal
Managing DirectorAppointment Date: 01-Dec-2019
Status: Current
MV
Mayank Verma Company SecretaryAppointment Date: 25-Jul-2019
Status: Current
Board Members(8)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Apr 2023 | ₹500.00 Cr | Open |
Others Creation Date: 12 Feb 2023 | ₹1,070.00 Cr | Open |
Hdfc Bank Limited Creation Date: 07 Nov 2022 | ₹197.50 Cr | Open |
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biocon, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biocon's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alert
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Related Corporates (Common Directorship)
8 years 6 months 
Recent activity within the organization
Director Appointment
Nicholas Robert Haggar was appointed as a Director was appointed as a Director on 01 Sep 2023 & has been associated with this company since 8 months 17 days .
01 Sep 2023Annual General Meeting
Biocon Limited last Annual general meeting of members was held on 11 Aug 2023 as per latest MCA records.
11 Aug 2023Director Appointment
Rekha Mehrotra Menon was appointed as a Director was appointed as a Director on 26 Jul 2023 & has been associated with this company since 9 months 24 days .
26 Jul 2023Charges
A charge with Others amounted to Rs. 500.00 cr with Charge ID 100775922 was registered on 28 Apr 2023.
28 Apr 2023Balance Sheet
Biocon Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Bangalore.
31 Mar 2023
Recent News, Updates & Announcement
- European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocons Proposed Biosimilars Trastuzumab and Pegfilgrastim.
PRNewswire Mylan NV NASDAQ TASE MYL and Biocon Ltd BSE code 532523 NSE BIOCON today announced that the European Medicines Agency EMA has.
PR Newswire 30 Nov 2017
- Biocon Introduces Oncologic Biosimilar KRABEVA In India.
Medicalbuyer 27 Nov 2017
- Biocon launches biosimilar bevacizumab for cancer treatment in India Mint.
Biocons biosimilar bevacizumab is indicated as a firstline treatment of patients with metastatic colorectal cancer and also used to treat lung kidney cervical ovarian and brain cancers.
mint 24 Nov 2017
Frequently asked questions
What is the Incorporation or founding date of Biocon Limited?
